Valeant Pharmaceuticals International, Inc. (VRX) Stock Rating Lowered by BidaskClub

Jay Anderson
June 20, 2017

Ftb Advsrs reported 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Deutsche Bank AG lowered their price target on shares of Valeant Pharmaceuticals International from $20.00 to $19.00 and set a "hold" rating for the company in a research report on Tuesday, March 7th. Marco Investment Management LLC's holdings in Valeant Pharmaceuticals International were worth $750,000 at the end of the most recent reporting period. It worsened, as 82 investors sold VRX shares while 87 reduced holdings. Valeant Pharmaceuticals International earned a news sentiment score of 0.20 on Alpha One's scale. Finally, Frontier Wealth Management LLC bought a new stake in Valeant Pharmaceuticals International during the fourth quarter worth about $149,000. J P Morgan Chase & Co reaffirmed a hold rating on shares of Valeant Pharmaceuticals International in a report on Tuesday, May 9th. LeJeune Puetz Investment Counsel LLC purchased a new stake in shares of Valeant Pharmaceuticals International during the fourth quarter worth approximately $123,000. The stock showed weekly downbeat performance of -0.57%, which was maintained for the month at -5.33%. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $32.74. (VRX) touched the day high at $13.63 while its day Low was at $12.99.

Market capitalization is just a fancy declare for a comprehensible concept: it is the market value of a company's outstanding shares. (VRX) stock price comparison to its moving averages, shares of company are 18.58% away from the 50-day moving average and 6.31% away from 20-day average. Credit Suisse Ag has 0.01% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Buy" rating given on Friday, November 20 by Mizuho. The specialty pharmaceutical company reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $0.87 by $1.93. The firm had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.17 billion. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. Valeant Pharmaceuticals International's revenue was down 11.1% on a year-over-year basis. During the same period previous year, the company posted ($1.08) EPS. City Financial Investment Co Ltd raised its position in shares of Valeant Pharmaceuticals International by 6.8% in the first quarter.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and republished in violation of U.S. and worldwide trademark and copyright laws.

Seattle officer in fatal shooting: 'I don't have a taser'
Ed Murray , the Mayor of Seattle , released a statement saying the shooting in Seattle was " a tragedy for all involved ". Police spokesman Detective Mark Jamieson says the woman had called police to report a burglary Sunday morning.

In Healthcare sector, shares of Valeant Pharmaceuticals International, Inc.

A number of equities analysts recently issued reports on the company. The correct version of this report can be accessed at https://www.thestockobserver.com/2017/06/20/valeant-pharmaceuticals-intl-inc-vrx-rating-reiterated-by-royal-bank-of-canada-updated.html. Morgan Stanley has "Equal-Weight" rating and $17 target. Finally, Wells Fargo & Company reissued an "underperform" rating and set a $11.50 price target on shares of Valeant Pharmaceuticals International in a research report on Thursday, February 23rd. Stifel Nicolaus maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Wednesday, March 16. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The firm has "Hold" rating by Canaccord Genuity given on Wednesday, March 16.

In other Valeant Pharmaceuticals Intl news, Director Schutter Richard Urbain De purchased 20,000 shares of the company's stock in a transaction that occurred on Thursday, May 11th. The shares were purchased at an average price of $13.90 per share, with a total value of $278,000.00. Following the completion of the transaction, the director now directly owns 70,572 shares of the company's stock, valued at approximately $980,950.80.

Other reports by BadHub

Discuss This Article

FOLLOW OUR NEWSPAPER